Oral Communications 2: Calcium and Bone | Part I | 0099 | ECE2024 | 26th European Congress of Endocrinology

ea0099oc2.1 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Encaleret (CLTX-305) sustained normalization of mineral homeostasis in patients with autosomal dominant hypocalcemia type 1 over 18 months in a phase 2 study [NCT04581629]

Gafni Rachel , Hartley Iris , Roszko Kelly , Pozo Karen , Nemeth Edward , Mathew Arun , Roberts Mary Scott , Adler Scott , Collins Michael

Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR ) variants, is characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. Conventional therapy (calcium and active vitamin D) can exacerbate hypercalciuria, which may result in renal complications. Calcilytics that act as negative allosteric modulators of the calcium-sensing receptor (CaSR), like ...

0 shares

ea0099oc2.2 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial

Schwarz Peter , Rejnmark Lars , Gosmanova Elvira , Khan Aliya , Makita Noriko , Imanishi Yasuo , Takeuchi Yasuhiro , Sprague Stuart , Shoback Dolores M. , Kohlmeier Lynn , Rubin Mishaela , Palermo Andrea , Gagnon Claudia , Tsourdi Elena , Zhao Carol , Makara Michael , Ominsky Michael , Lai Bryant , Ukena Jenny , Sibley Christopher , Shu Aimee

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) are at increased risk for renal complications and declines in renal function. In clinical trials, palopegteriparatide treatment enabled independence from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and maintained serum biochemistr...

9 shares

ea0099oc2.3 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

A translational approach to investigate the mechanism whereby eneboparatide induces prolonged calcium normalization in patients with chronic hypoparathyroidism

Ravel Guillaume , Datta Rakesh , Milano Stephane , Ovize Michel , Allas Soraya , Aouadi Myriam , Culler Michael

Maintaining normal serum and urinary calcium in patients with chronic hypoparathyroidism (cHP) remains a therapeutic challenge. Parathyroid hormone (PTH) replacement therapy is not ideal due to its short half-life and transient activation of the PTH 1 receptor (PTH1R). Eneboparatide is a hybrid analog of PTH and PTH-related peptide specifically designed to induce prolonged activation of the PTH1R. Despite a short half-life, eneboparatide is able to normalize serum and urinary ...

2 shares

ea0099oc2.4 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Increased urinary excretion of calcium and nephrolithiasis: Real-life data from the epi-hypo cohort of hypoparathyroidism patients

Jean-Philippe Bertocchio , Christelle Nidercorn , Kamenicky Peter , Marie Christine Vantyghem , Gerard Maruani , Groussin Lionel , Ovize Michel , Linglart Agnes , Houillier Pascal

Introduction: In chronic hypoparathyroidism (cHP), hypercalciuria is frequent, the mechanism of which remains unclear. The repetition of episodes of urinary tract obstruction by lithiasis can play a key role in the progressive deterioration of renal function. Taking advantage of the prospective cohort Epi-Hypo, we examined the relationship between nephrolithiasis and hypercalciuria.Methods: The Epi-Hypo cohort started in 2016 in France and is still activ...

0 shares

ea0099oc2.5 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Remaining secretion of parathyroid hormone is associated with calcium excretion in chronic hypoparathyroidism

Jean-Philippe Bertocchio , Christelle Nidercorn , Kamenicky Peter , Marie Christine Vantyghem , Gerard Maruani , Groussin Lionel , Ovize Michel , Linglart Agnes , Houillier Pascal

Introduction: In Chronic hypoparathyroidism (cHP), secretion of parathyroid hormone (PTH) is insufficient to maintain blood calcium concentration (PCa) steady. More than 70% of cases result from neck surgery and therefore in insufficient secretion of PTH as in mutations of genes involved in PTH synthesis, while mutations of the calcium-sensing receptor (CaSR) and its signaling pathway may result in a remaining secretion of PTH. cHP can exert nephrocalcinosis and/or nephrolithi...

0 shares

ea0099oc2.6 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]

Rejnmark Lars , Mannstadt Michael , Brandi Maria Luisa , Ozono Keiichi , Tebben Peter , Mathew Arun , Roberts Mary Scott , Adler Scott , Gafni Rachel

Autosomal dominant hypocalcemia type 1 (ADH1), caused by pathogenic gain-of-function calcium-sensing receptor gene (CASR ) variants, is characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. Current standard-of-care (SoC) (calcium and active vitamin D) can exacerbate hypercalciuria, which may result in renal complications. Encaleret is an investigational oral calcilytic, functioning as a negative allo...

4 shares

Endocrine Abstracts

26th European Congress of Endocrinology